Today, the EVP & GC of BioMarin (NASDAQ: BMRN), George Eric Davis, sold shares of BMRN for $220.4K.
In addition to George Eric Davis, 4 other BMRN executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on BioMarin’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $377 million and GAAP net loss of $16.79 million. In comparison, last year the company earned revenue of $316 million and had a GAAP net loss of $36.83 million. Currently, BioMarin has an average volume of 1.28M.
Based on 9 analyst ratings, the analyst consensus is Strong Buy with an average price target of $117.33, reflecting a 17.8% upside.
The insider sentiment on BioMarin has been negative according to 118 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its products include BioMarin, Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim.
